Factors associated with initiation of antihyperglycaemic medication in UK patients with newly diagnosed type 2 diabetes

Table 2 Adjusted hazard ratios for initiation of antihyperglycaemic treatment

Variable	Patient Sample (N = 9,158)
	Hazard Ratio (95% CI)	P-value
Baseline ^a
Age at first diagnosis, years	0.98 (0.97, 0.99)	< 0.0001
HbA_1c ≥ 7.5%	2.44 (1.61, 3.70)	< 0.0001
Dummy HbA_1c (missing = 1)	1.62 (1.06, 2.47)	0.0247
Interaction: Age with HbA_1c ≥ 7.5%	1.015 (1.008, 1.022)	< 0.0001
Gender (male = 1; female = 0)	0.91 (0.86, 0.97)	0.0018
Physician registration years	1.007 (1.003, 1.011)	0.0005
Lipid-modifying agents	1.22 (1.12, 1.32)	< 0.0001
Weight-reducing agents	1.59 (1.27, 1.99)	< 0.0001
New at follow up
Cardiovascular conditions	1.36 (1.16, 1.59)	0.0001
Antihypertensive agents	1.43 (1.28, 1.61)	< 0.0001
Lipid-modifying agents	2.41 (2.21, 2.62)	< 0.0001
Gastroprotective agents	1.59 (1.36, 1.88)	< 0.0001
Weight-reducing agents	1.38 (1.06, 1.81)	0.0175
Hospitalization	1.37 (1.22, 1.54)	< 0.0001

^aBaseline variables assessed in 12-month period prior to diagnosis of type 2 diabetes. Non-significant predictors included in the model were indicators for baseline cardiovascular conditions, microvascular conditions, cerebrovascular conditions, cancer, liver disease, Alzheimer's disease/dementia, peptic ulcer disease, rheumatic conditions, chronic pulmonary disease, hemi- or paraplegia, oedema, antihypertensive medication use, and gastroprotective medication use, and indicators for follow-up microvascular conditions, cancer, oedema, liver disease and Alzheimer's disease/dementia.

ISSN: 1472-6823